The Pharmaceutical Journal
Vol 275 No 7357 p42
9 July 2005

This article
Reprint   Photocopy

  Acrobat Reader

News summary

MAb for diabetes

Short-term treatment with a monoclonal antibody against CD3 T cells helps preserve residual beta cell function and stops insulin requirements rising for the first 18 months after diagnosis of type 1 diabetes. Patients treated with the antibody suffered a moderate flu-like syndrome (New England Journal of Medicine 2005;352:2598).